AbbVie Ventures
Overview
Biopharmaceutical company developing treatments across multiple areas.
Founded
2013
Deals ยท 12mo
3
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Cloverleaf Bio | Sep 2026Participated | $33 MSeed | |
Third Arc Bio | Feb 2026Participated | $52 MSeries A | |
DISCO Pharmaceuticals | Dec 2025Participated | $42 MSeed | |
Light Horse Therapeutics | Jan 2025Participated | $62 MSeries A | |
Oisin Biotechnologies | Jul 2024Led | $15 MSeries A | |
Third Arc Bio | Jul 2024Participated | $165 MSeries A | |
Accent Therapeutics | Jan 2024Participated | $75 MSeries C | |
DISCO Pharmaceuticals | Jan 2024Participated | $22 MSeed | |
Quanta Therapeutics | Jun 2023Participated | $51 MSeries D | |
Mozart Therapeutics | Jun 2023Participated | $25 MSeries A | |
AmbAgon Therapeutics | Jan 2022Participated | $85 MSeries A | |
Nitrase Therapeutics | Nov 2021Participated | $45 MSeries A | |
Cloverleaf Bio | Sep 2026Participated | $33 MSeed | |
Third Arc Bio | Feb 2026Participated | $52 MSeries A | |
DISCO Pharmaceuticals | Dec 2025Participated | $42 MSeed | |
Light Horse Therapeutics | Jan 2025Participated | $62 MSeries A | |
Oisin Biotechnologies | Jul 2024Led | $15 MSeries A | |
Third Arc Bio | Jul 2024Participated | $165 MSeries A | |
Accent Therapeutics | Jan 2024Participated | $75 MSeries C | |
DISCO Pharmaceuticals | Jan 2024Participated | $22 MSeed | |
Quanta Therapeutics | Jun 2023Participated | $51 MSeries D | |
Mozart Therapeutics | Jun 2023Participated | $25 MSeries A | |
AmbAgon Therapeutics | Jan 2022Participated | $85 MSeries A | |
Nitrase Therapeutics | Nov 2021Participated | $45 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 4 |
| Series A | 6 | 21 |
| Series B | 0 | 7 |
| Series C+ | 0 | 7 |
| Other Equity | 0 | 4 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jun '13 | 1 |
| Jul '13 | 0 |
| Aug '13 | 0 |
| Sep '13 | 0 |
| Oct '13 | 0 |
| Nov '13 | 0 |
| Dec '13 | 0 |
| Jan '14 | 0 |
| Feb '14 | 0 |
| Mar '14 | 0 |
| Apr '14 | 0 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 1 |
| Aug '14 | 0 |
| Sep '14 | 1 |
| Oct '14 | 0 |
| Nov '14 | 0 |
| Dec '14 | 0 |
| Jan '15 | 0 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 0 |
| Jul '15 | 0 |
| Aug '15 | 0 |
| Sep '15 | 0 |
| Oct '15 | 0 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 3 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 1 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 1 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 1 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 1 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 2 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 2 |
| Nov '17 | 0 |
| Dec '17 | 1 |
| Jan '18 | 0 |
| Feb '18 | 1 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 1 |
| Jul '18 | 1 |
| Aug '18 | 3 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 2 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 1 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 1 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 2 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 1 |
| Aug '20 | 0 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 1 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 1 |
| Jul '21 | 2 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 1 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 2 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 2 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 2 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 1 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 1 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 49 |
| Manufacturing | 3 |
| Space & Frontier Tech | 3 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 5 |
| $10M-$25M | 8 |
| $25M-$50M | 15 |
| $50M-$100M | 17 |
| $100M-$250M | 4 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 41 |
| Europe | 7 |
| Australia | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Alexandria Venture Investments | 16 |
| Pfizer Ventures | 10 |
| Eli Lilly and Company | 8 |
| Dementia Discovery Fund | 7 |
| Johnson & Johnson Innovation | 7 |
| Polaris Partners | 7 |
| Sofinnova Partners | 7 |
| ARCH Venture Partners | 6 |
| MRL Ventures Fund | 6 |
| BVF Partners | 5 |
| Google Ventures | 5 |
| M Ventures | 5 |
| Surveyor Capital | 5 |
| SV Health Investors | 5 |
| Watson Fund | 5 |
| WuXi AppTec | 5 |
| Amgen Ventures | 4 |
| Bristol Myers Squibb | 4 |
| Mission Bay Capital | 4 |
| Novartis | 4 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 6 | 12% |
| Participating | 43 | 88% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 17% |
| Co-led | 5 | 83% |
Team
Psychiatry Specialty Representative
Architect, Technology II
Managing Director
Executive Vice President, Chief Business and Strategy Officer
Chairman of the Board & Chief Executive Officer
Executive Vice President, Research & Development and Chief Scientific Officer
Founder
Principal Scientist
Distinguished Research Fellow
Associate Vice President, Marketing Analytics & Business Insights